RxDoctor Payments Data

Jane McGrath

Psychiatric/Mental Health · Nashua, NHNPI 1134214265

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 67 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by AbbVie at 42.7% of the total. Reporting peaked in 2021 at $493 and has fallen 69.4% since, to $151 in 2025.

$1,712in general payments, 2019–2025

Across 67 payments — averaging $25.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$731
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$283
  • Axsome Therapeutics, Inc.$203
  • Lundbeck LLC$102
  • Bausch Health US, LLC$90
  • Tactile Systems Technology Inc$81
  • plus $223 from 7 others

What the payments were for

  • Food & beverage$1,712100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,712 in reported general payments places this provider in the 80th percentile of 264 psychiatric/mental health providers in New Hampshire.

See all psychiatric/mental health providers in New Hampshire

Medicare billing

Part B allowed, 2024
$21,555
Medicare patients
48
Services billed
213

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole26$50,493
Adderall XrDextroamphetamine/Amphetamine17$8,151
Aripiprazole114$7,128
VyvanseLisdexamfetamine Dimesylate11$4,866
Duloxetine Hcl106$2,196
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine72$1,834
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine32$1,530
Methylphenidate Hcl47$1,039
Clonazepam100$985
Lamotrigine98$955
Escitalopram Oxalate120$925
Venlafaxine Hcl ErVenlafaxine Hcl31$757
Clorazepate Dipotassium12$739
Bupropion XlBupropion Hcl48$737
Desvenlafaxine Succinate ErDesvenlafaxine Succinate28$722

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$13$4,86611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 264 psychiatric/mental health providers in New Hampshire.

Other psychiatric/mental health in Nashua

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →